Lixte Biotechnology Holdings Inc LIXT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $6.89
- Day Range
- $6.91–7.50
- 52-Week Range
- $0.66–7.50
- Bid/Ask
- $5.32 / $9.06
- Shares Outstanding
- 17.39M
- Market Cap
- $126.05M
- Volume/Avg
- 442,108 / 94,272
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3
- Website
- https://www.lixte.com
Valuation
|
Metric
|
LIXT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.14 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LIXT
|
|---|---|
Quick Ratio | 2.65 |
Current Ratio | 2.78 |
Interest Coverage | −799.29 |
Quick Ratio
LIXT
Profitability
|
Metric
|
LIXT
|
|---|---|
Return on Assets (Normalized) | −81.38% |
Return on Equity (Normalized) | −156.07% |
Return on Invested Capital (Normalized) | −91.85% |
Return on Assets
LIXT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Yggrmqxr | Lcjgxyv | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Svkzxqhhs | Klzylk | $63B | |||
| argenx SE ADR
ARGX
| Gqpgjqz | Srls | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hbkvrbzr | Cvpbft | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Lvygzkgrzh | Lpfkq | $24B | |||
| BioNTech SE ADR
BNTX
| Qstpftg | Mtsw | $22B | |||
| Incyte Corp
INCY
| Kdgncgy | Wndkb | $21B | |||
| Moderna Inc
MRNA
| Sfgzjkxx | Kskf | $18B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Hppkxch | Vvp | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Jsvlftxs | Lgclr | $13B |
United States